Insulet Corp.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2.71B | $2.07B | $1.70B | $1.31B | $1.10B | $904.1M | $736.2M |
| U.S. Omnipod | — | — | $1.62B | $1.26B | $893.9M | $701.0M | $582.4M | $435.5M |
| International Omnipod | — | — | $419.0M | $393.9M | $340.5M | $330.1M | $264.4M | $244.5M |
| Drug Delivery | — | — | $31.3M | $41.4M | $70.8M | $67.2M | $57.3M | $56.2M |
| Neighborhood Diabetes | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | $768.2M | $625.9M | $537.2M | $499.7M | $346.7M | $322.1M | $257.9M |
| Gross Profit | — | $1.94B | $1.45B | $1.16B | $805.6M | $752.1M | $582.3M | $480.3M |
| Gross Margin | — | 71.6% | 69.9% | 68.3% | 61.7% | 68.5% | 64.4% | 65.2% |
| Operating Expenses | ||||||||
| Research & Development | — | $301.1M | $219.6M | $205.0M | $180.2M | $160.1M | $146.8M | $132.3M |
| SG&A Expense | — | $1.17B | $917.2M | $734.8M | $587.8M | $466.0M | $384.0M | $298.0M |
| Operating Income | — | $473.8M | $308.9M | $220.1M | $37.6M | $126.0M | $51.5M | $50.0M |
| Operating Margin | — | 17.5% | 14.9% | 13.0% | 2.9% | 11.5% | 5.7% | 6.8% |
| Interest Expense | — | — | — | $36.2M | $36.0M | $61.7M | $48.1M | $34.6M |
| Pretax Income | — | $339.5M | $300.2M | $214.7M | $9.8M | $20.5M | $9.7M | $14.5M |
| Income Tax Expense | — | $92.4M | $-118.1M | $8.3M | $5.2M | $3.7M | $2.9M | $2.9M |
| Net Income | — | $247.1M | $418.3M | $206.3M | $4.6M | $16.8M | $6.8M | $11.6M |
| Net Margin | — | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | 0.8% | 1.6% |
| EPS (Basic) | — | $3.51 | $5.97 | $2.96 | $0.07 | $0.25 | $0.11 | $0.19 |
| EPS (Diluted) | — | $3.48 | $5.78 | $2.94 | $0.07 | $0.24 | $0.10 | $0.19 |
| Shares Outstanding (Basic) | 70.4M | 70.3M | 70.1M | 69.8M | 69.4M | 67.7M | 64.7M | 60.6M |
| Shares Outstanding (Diluted) | 70.4M | 71.9M | 73.9M | 73.6M | 69.9M | 68.6M | 65.9M | 62.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |